unimportant decoration Nano-scale droplet illustration

About BlueWillow Biologics

unimportant decoration

BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of Michigan, employs novel oil-in-water nano-droplets as an intranasal adjuvant that elicits a robust mucosal and a Th1-biased systemic immune response.  This NanoVax® platform has established proof of concept in humans and enables intranasal vaccines for challenging respiratory infections and sexually transmitted infections as well as immunotherapy for food allergies. The company’s lead candidates include intranasal vaccines for Covid-19 (booster), HSV-2, RSV, Anthrax and influenza and intranasal immunotherapy for peanut allergy.